Share
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma. we are going to quarterly, and we are going to talk about the market: Hey, what is pharma doing out there in clinical trials? Combing clinicaltrials.gov and approach them, and say could a combined solution like ours advance our clinical trials?” Valerie Sullivan, CEO of etectRx told